Preclinical Studies


Warning: preg_replace() [function.preg-replace]: Unknown modifier '1' in /home/content/96/5373796/html/cbdcasestudies.com/wp-content/plugins/jetpack/class.photon.php on line 345

Puriskin by Vanessa Blake Cosmetics enter the pain-relief and CBD Market NEW YORK, NEW YORK (NY), UNITED STATES, April 3, 2017 /EINPresswire.com/ — Natural, British skincare brand Puriskin by Vanessa Blake Cosmetics, widen their market reach with an expansion into the pain-relief sector and the rapidly evolving CBD industry. Puriskin CBD Therapy, is the emerging wellness […]

Canadian researchers are testing mice to see if cannabinoid oil products — a common medical marijuana treatment — could help alleviate the neuropathic pain that often afflicts patients with multiple sclerosis (MS). The preclinical study, “Identifying the molecular mechanisms involved in supressing multiple sclerosis induced neuropathic pain following cannabinoid treatment in an animal model of multiple sclerosis (MS),” […]

by

NEW YORK, March 01, 2017 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, began production of CanChew Plus™, the next generation of the company’s award-winning controlled-release cannabidiol (CBD) functional chewing gum. CanChew® is the world’s first patented controlled-release cannabinoid chewing gum containing 50 mg of hemp […]

Editorial: J. Stephen McIver, EditorAdvertising: Maureen Dwyer Liberti, Vice President, Group PublisherProduction: Dawn Flook, Director of Production ServicesCirculation: Jackie Ott, Circulation ManagerWebmaster: Webmaster … read more at: https://www.ptcommunity.com/news/20170206/biopharma-companies-mix-medications-and-cannabis

Daily consumption of krill oil may boost learning and working memory in lab animals, and display antidepressant-like effects, according to a new study from Aker BioMarine. Lab rats who received daily krill oil supplements (Superba krill oil, Aker) performed better in cognitive tests, compared to control animals, according to findings published in Lipids in Health […]

The FDA has given clearance to NeuroRx to proceed with a phase 2B/3 study protocol under an investigational new drug application for NRX-101, the first oral therapy for acute suicidal ideation and behavior (ASIB). The goal of the trials is to exhibit the effectiveness and safety of NRX-101 as a means of maintaining remission in patients […]

by

(Reuters) – BioCryst Pharmaceuticals Inc said on Monday a dose of its experimental antiviral drug improved survival rates in mice infected with the Zika virus in a preclinical study. Two doses of the drug, BCX443, were tested against a placebo and an oral antiviral called ribavarin for their effect on survival of immune-deficient mice infected […]

by

Combinations of Arbutus RNAi and Capsid Assets and Approved Drugs Show Complementary ActionCapsid Inhibitor AB-423 Has Dual Mode of Action; Inhibits HBV DNA and cccDNA SynthesisSecond Generation RNAi Agent ARB-1740 Improves Upon Potency of Lead RNAi Program VANCOUVER, B.C. and DOYLESTOWN, Pa., Nov. 14, 2016 — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus […]

by

LOS ANGELES–(BUSINESS WIRE)–Phytecs is expanding its preclinical research program on its novel fluorinated cannabidiol, HUF-101, along with its family of related drug molecules developed by noted medicinal chemist and Phytecs Director of Global Research, Prof. Raphael Mechoulam of The Hebrew University of Jerusalem. A new preclinical study found HUF-101 effective in mice models predictive of […]

by

PULLMAN, Wash., July 28 (UPI) — The breakdown of muscle often accompanies chronic or long-term disease, making disease worse and sometimes hastening death, and doctors have no way to stop or slow it. Researchers at Washington State University devised a method of delivering gene therapy to stop muscle wasting without affecting other functions of the […]

by

Click here to receive IBD news via e-mail GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing new therapeutics from its cannabinoid product platform and that commercialized the world’s first plant-derived cannabinoid prescription drug Sativex® for spasticity (rigid muscles), recently presented the preliminary top line results from a Phase 2a ulcerative colitis […]

by

PHOENIX, Aug. 18, 2016 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate. The study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of […]

by